# Nematicity Arising from a Chiral Superconducting Ground State in Magic-Angle Twisted Bilayer Graphene under In-Plane Magnetic Fields

Article · Tao Yu, Dante M. Kennes, Angel Rubio, Michael A. Sentef

- Archive id: arxiv:2101.01426
- Published: 2021-01-05
- Venue: Phys. Rev. Lett. 127, 127001 (2021)
- DOI: https://doi.org/10.1103/physrevlett.127.127001
- arXiv: https://arxiv.org/abs/2101.01426
- Citations: 20
- Source URL: https://arxiv.org/abs/2101.01426
- PDF: https://arxiv.org/pdf/2101.01426
- Provenance: arxiv

## Abstract

Recent measurements of the resistivity in magic-angle twisted bilayer graphene near the superconducting transition temperature show two-fold anisotropy, or nematicity, when changing the direction of an in-plane magnetic field \[Cao \\textit{et al.}, Science \\textbf{372}, 264 (2021)\]. This was interpreted as strong evidence for exotic nematic superconductivity instead of the widely proposed chiral superconductivity. Counter-intuitively, we demonstrate that in two-dimensional chiral superconductors the in-plane magnetic field can hybridize the two chiral superconducting order parameters to induce a phase that shows nematicity in the transport response. Its paraconductivity is modulated as $\\cos(2θ\_{\\bf B})$, with $θ\_{\\bf B}$ being the direction of the in-plane magnetic field, consistent with experiment in twisted bilayer graphene. We therefore suggest that the nematic response reported by Cao \\textit{et al.} does not rule out a chiral superconducting ground state.

_Abstract reproduced under CC0-1.0 (arXiv descriptive metadata)._

Topics: [Moire & 2D Superconductivity](https://space-kitty.com/topics/moire-superconductivity)

Cited in dossiers:
- [Moire & 2D Superconductivity: State of the Field (October 2026)](https://space-kitty.com/dossiers/moire-superconductivity)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.